Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

PZ Cussons has decided to leave Nigeria, citing naira's devaluation as the reason after GSK, Sanofi and other multinationals ...

Flagship Pioneering has signed yet another strategic-level deal with a big pharma group, with GSK the latest to tap into its network of biotech companies in an alliance that could be worth more ...

The FTSE 100 group won the case ... could change into NDMA when exposed to heat. However, GSK, Pfizer and the other companies ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

GSK has pushed back on US claims it is ... s Federal Trade Commission alleged the pharmaceutical group was one of several companies that could be keeping branded drug prices “artificially ...

Chris is a chartered mechanical engineer who has worked for the GSK group of companies in a range of engineering roles for over 30 years. He has worked at six pharmaceutical manufacturing sites in the ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

This solidified GSK as a "here-to-stay" company in the market ... and he held the position of Vice-Chairman for PhRMA Local Working Group in Jordan.

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

Key Insights Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their ...

Moreover, consensus analysts’ expectations are that GSK’s earnings will grow by 14.4% a year to the end of 2026. Ultimately, rises in earnings power a company’s share price (and dividends) higher over ...